Stereochemistry | RACEMIC |
Molecular Formula | C13H21NO3 |
Molecular Weight | 239.3107 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1
InChI
InChIKey=NDAUXUAQIAJITI-UHFFFAOYSA-N
InChI=1S/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3
Molecular Formula | C13H21NO3 |
Molecular Weight | 239.3107 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Levalbuterol is the (R)-enantiomer of the drug substance racemic albuterol (salbutamol). Binding studies have demonstrated that (R)-albuterol binds to the beta2-adrenergic receptor with a high affinity, whereas (S)-albuterol binds with 100-fold less affinity than (R)-albuterol. Other evaluations have suggested that (R)-albuterol possesses the bronchodilatory, bronchoprotective, and ciliary-stimulatory properties of racemic albuterol, while (S)-albuterol does not contribute beneficially to the therapeutic effects of the racemate and was originally assumed to be inert. Xopenex (levalbuterol HCl) Inhalation Solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease.
Originator
Approval Year
Cmax
AUC
Doses
AEs
Sourcing
PubMed
Patents
Sample Use Guides
Children 6–11 years old: The recommended dosage of Xopenex (levalbuterol HCl)
Inhalation Solution for patients 6–11 years old is 0.31 mg administered three times a day, by
nebulization. Routine dosing should not exceed 0.63 mg three times a day.
Adults and Adolescents ≥12 years old: The recommended starting dosage of Xopenex
(levalbuterol HCl) Inhalation Solution for patients 12 years of age and older is 0.63 mg
administered three times a day, every 6 to 8 hours, by nebulization.
Route of Administration:
Respiratory